Spectrum Pharma says FDA rejects its bladder cancer drug

Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration rejected the drugmaker's bladder cancer treatment.

The company said it was considering a new smaller study for the drug, apaziquone, that would replace the ongoing late-stage study in which patient enrolment has been stopped.